Literature DB >> 3383477

Semiconstrained elbow prostheses with special reference to the GSB III prosthesis.

N Gschwend1, J Loehr, D Ivosevic-Radovanovic, H Scheier, U Munzinger.   

Abstract

Fully constrained metal-to-metal elbow prostheses are not used anymore because of a high loosening rate. Today semiconstrained or condylar prostheses are the two possibilities when replacement of a destroyed elbow joint is considered. A careful analysis of the most recent publications in the world literature reveals a high complication rate for both types of prostheses, each one having specific advantages and disadvantages. The Gschwend-Scheier-Bähler (GSB) III prosthesis is a semiconstrained prosthesis, requires little bone resection, and is therefore easily salvaged. The results in regard to pain relief and improvement in range of motion are satisfactory in a high percentage of patients. The rate of lasting complications is lower than with most of the other prostheses. The authors' transtricipital approach is also a factor that contributes to the high success rate. In case of a failed arthroplasty the authors' method of reconstructing the humeral condyles allows a better salvage.

Entities:  

Mesh:

Year:  1988        PMID: 3383477

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  5 in total

1.  [Arthroplasty for rheumatic elbow joints].

Authors:  G Heers; J Grifka
Journal:  Z Rheumatol       Date:  2011-07       Impact factor: 1.372

Review 2.  [Dislocation after total elbow arthroplasty].

Authors:  M John; K Schenk; S Lieske; H W Neumann
Journal:  Orthopade       Date:  2007-10       Impact factor: 1.087

3.  [The Guepar total elbow arthroplasty].

Authors:  J Y Alnot; B Augereau; P Bellemère
Journal:  Int Orthop       Date:  1994-04       Impact factor: 3.075

Review 4.  [Differential arthroplasty and endoprosthesis indications in rheumatoid arthritis of the elbow joint].

Authors:  B F Morrey
Journal:  Orthopade       Date:  2003-11       Impact factor: 1.087

5.  [Not Available].

Authors:  H K Schwyzer; N Gschwend; J Loehr; B Simmen
Journal:  Oper Orthop Traumatol       Date:  1998-03       Impact factor: 1.286

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.